Cardiac autonomic neuropathy in type 2 diabetes
Conditions
Interventions
control group:Addition of methylcobalamin dispersible tablets to conventional treatment
experimental group:Addition of Jianxin Capsules to conventional treatment
Sponsors
Rugao Hospital of Traditional Chinese Medicine, Jiangsu Province
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Those who meet the diagnostic criteria of western medicine diabetes cardiac autonomic neuropathy and TCM syndrome differentiation criteria of phlegm and blood stasis; (2) At the time of enrollment, blood glucose control was up to standard, with blood pressure = 140/90mmHg; (3) Age range from 30 to 75 years old; (4) I have not taken any medication that interferes with the study in the past 4 weeks (such as ß Receptor blockers; (5) Volunteer and fill out an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those who do not meet the inclusion criteria; (2) There are other neurological causes, such as cervical and lumbar spondylosis, cerebral infarction, and Guillain Barre syndrome; (3) Those who have a history of refractory hypertension, angina pectoris, myocardial infarction, heart failure, acute Cerebrovascular disease, DKA and other acute and serious diseases in the past six months, as well as those with concurrent infection; (4) Pregnant and lactating women; (5) There are serious primary diseases such as cardiovascular, cerebrovascular, liver, hematopoietic system, arteriovenous diseases, or serious diseases that affect their survival, such as malignant tumors or AIDS; (6) Those who are unable to provide sufficient emotional consent due to intellectual or behavioral impairments; (7) Suspected or confirmed history of alcohol or drug abuse; (8) According to the judgment of the researcher, other lesions that reduce the likelihood of enrollment or complicate enrollment, frequent changes in the work environment, and other situations that may lead to loss of follow-up; (9) Individuals with allergic constitution or known allergies to the ingredients in this group; (10) Patients participating in clinical research on other drugs;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart rate variability;Nuclear factor E2 related factor 2;heme oxygenase-1;catalase;superoxide dismutase;glutathione peroxidase; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucose metabolism indicators;blood pressure;blood fat;Quantitative integration of traditional Chinese medicine symptoms; | — |
Countries
China
Contacts
Public ContactPu Qiang
Rugao Hospital of Traditional Chinese Medicine, Jiangsu Province
Outcome results
None listed